S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
A gold storm is coming… (Ad)
Europe bans Russian diesel, other oil products over Ukraine
Gas prices dip in NJ, around nation as cold weather returns
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
A gold storm is coming… (Ad)
Europe bans Russian diesel, other oil products over Ukraine
Gas prices dip in NJ, around nation as cold weather returns
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
A gold storm is coming… (Ad)
Europe bans Russian diesel, other oil products over Ukraine
Gas prices dip in NJ, around nation as cold weather returns
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
A gold storm is coming… (Ad)
Europe bans Russian diesel, other oil products over Ukraine
Gas prices dip in NJ, around nation as cold weather returns
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
NASDAQ:EKSO

Ekso Bionics - EKSO Stock Forecast, Price & News

$1.70
0.00 (0.00%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.70
$1.77
50-Day Range
$1.04
$1.88
52-Week Range
$1.03
$3.15
Volume
30,066 shs
Average Volume
53,570 shs
Market Capitalization
$22.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Ekso Bionics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
429.4% Upside
$9.00 Price Target
Short Interest
Healthy
0.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.46mentions of Ekso Bionics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$15,464 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

545th out of 1,028 stocks

General Industrial Machinery, Industry

4th out of 10 stocks

EKSO stock logo

About Ekso Bionics (NASDAQ:EKSO) Stock

Ekso Bionics Holdings, Inc. engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. It operates through the following segments: EksoHealth and EksoWorks. The EksoHealth segment consists of the engineering, manufacture, and sale of exoskeletons for applications in the medical markets. The EksoWorks segment offers exoskeleton devices to allow able-bodied users to perform heavy duty work for extended periods. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Receive EKSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter.

EKSO Stock News Headlines

A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
StockNews.com Initiates Coverage on Ekso Bionics (NASDAQ:EKSO)
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
See More Headlines
Receive EKSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter.

EKSO Company Calendar

Last Earnings
11/01/2021
Today
2/05/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
General industrial machinery,
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EKSO
Previous Symbol
OTCMKTS:EKSOD
Employees
55
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+429.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-9,760,000.00
Net Margins
-109.88%
Pretax Margin
-109.88%

Debt

Sales & Book Value

Annual Sales
$11.25 million
Book Value
$2.94 per share

Miscellaneous

Free Float
12,741,000
Market Cap
$22.34 million
Optionable
Not Optionable
Beta
1.70

Key Executives

  • Scott Davis
    Chief Executive Officer & Director
  • Jerome Wong
    Chief Financial Officer, Secretary & Controller
  • Charlie Wu
    Senior Director-Operations
  • Stephan Aderhold
    Vice President-EMEA Sales & Marketing
  • Jason Jones
    Vice President-Product Development













EKSO Stock - Frequently Asked Questions

Should I buy or sell Ekso Bionics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EKSO shares.
View EKSO analyst ratings
or view top-rated stocks.

What is Ekso Bionics' stock price forecast for 2023?

1 equities research analysts have issued 12-month price objectives for Ekso Bionics' shares. Their EKSO share price forecasts range from $9.00 to $9.00. On average, they expect the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 429.4% from the stock's current price.
View analysts price targets for EKSO
or view top-rated stocks among Wall Street analysts.

How have EKSO shares performed in 2023?

Ekso Bionics' stock was trading at $1.19 on January 1st, 2023. Since then, EKSO stock has increased by 42.9% and is now trading at $1.70.
View the best growth stocks for 2023 here
.

Are investors shorting Ekso Bionics?

Ekso Bionics saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 68,600 shares, an increase of 36.4% from the December 31st total of 50,300 shares. Based on an average daily volume of 52,800 shares, the short-interest ratio is currently 1.3 days. Currently, 0.6% of the company's shares are sold short.
View Ekso Bionics' Short Interest
.

When is Ekso Bionics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our EKSO earnings forecast
.

How were Ekso Bionics' earnings last quarter?

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) posted its earnings results on Monday, November, 1st. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.10. The company earned $3.05 million during the quarter, compared to analysts' expectations of $2.58 million. Ekso Bionics had a negative net margin of 109.88% and a negative trailing twelve-month return on equity of 45.07%. During the same period last year, the business posted ($0.52) EPS.

When did Ekso Bionics' stock split?

Ekso Bionics's stock reverse split on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 4th 2016. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of Ekso Bionics own?
What is Ekso Bionics' stock symbol?

Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO."

Who are Ekso Bionics' major shareholders?

Ekso Bionics' stock is owned by many different institutional and retail investors. Top institutional investors include Essex Investment Management Co. LLC (3.38%), Legato Capital Management LLC (0.29%), Strategic Wealth Investment Group LLC (0.22%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Jason C Jones, Jerome Wong, John Glenn, Scott G Davis and Steven Sherman.
View institutional ownership trends
.

How do I buy shares of Ekso Bionics?

Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ekso Bionics' stock price today?

One share of EKSO stock can currently be purchased for approximately $1.70.

How much money does Ekso Bionics make?

Ekso Bionics (NASDAQ:EKSO) has a market capitalization of $22.34 million and generates $11.25 million in revenue each year. The company earns $-9,760,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.

How can I contact Ekso Bionics?

Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The official website for the company is www.eksobionics.com. The company can be reached via phone at (510) 984-1761, via email at investors@eksobionics.com, or via fax at 510-927-2647.

This page (NASDAQ:EKSO) was last updated on 2/5/2023 by MarketBeat.com Staff